IOVA·Nasdaq·US
Iovance
Iovance is a commercial-stage biotechnology company focused on tumor-infiltrating lymphocyte, or TIL, cell therapies for cancer. The company generates product revenue primarily from Amtagvi and Proleukin.
Recent Activity
Updated Oct 31, 2026
–Iovance Biotherapeutics announced it will host a live webcast at 8:30 a.m. ET on October 29, 2026 to discuss positive data for its TIL therapy in metastatic non-small cell lung cancer (mNSCLC) and its broader precision medicine strategy.
–Iovance Biotherapeutics will report third quarter 2026 financial results and corporate updates on Thursday, November 5, 2026.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.